Fredun Pharmaceuticals Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹2,261 Cr
- P/E
- 50.87
- ROE
- 15.81%
- PEG
- 1.12
- Price to sales
- 3.03
- Debt to equity
- 0.80
- 52W high / low
- ₹2,858 / ₹886
- Sales growth (5Y)
- 36.54%
- EBITDA margin
- 14.79%
- Net profit margin
- 5.23%
- Promoter holding
- 44.57%
- Sales (last year)
- ₹748 Cr
Incorporated in 1987, Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals products[1]
Guidance scorecard · Q1 FY27 call
What Fredun Pharmaceuticals Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
RevenueQ4 FY26 call
20–40%- The company targets a top-line growth of 25% to 30% annually for FY '27 and the next few years.
- Growth has been steady with a 32% CAGR over the last 19 years, with no degrowth year.
- New age businesses like Pet Care, Mobility, and Nutraceuticals are growing rapidly at 40% to 50% CAGR from smaller bases.
- Vintage pharmaceutical business is growing steadily at 10% to 15%.
- Working capital and cash flows have improved, supporting growth without financial strain.
- EBITDA margins expected to improve over the next 8-9 quarters with a potential spike in profitability as new products saturate demographic reach within 2.5 to 3 years.
2 more points from Fredun Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
Up 2%+See what Fredun Pharmaceuticals Ltd said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- Fredun Pharmaceuticals is actively expanding manufacturing capacity, adding 12 to 13 packing lines by the end of September 2026.
- A new wing is being constructed within their existing plant to further enhance production capabilities.
- The company plans to become one of the top 3-4 manufacturing plants in capacity in the country within the next 2.5 years, leveraging its cluster of 4 plants at one location.
- Facilities are being set up for functional foods and planning to manufacture various wet food products.
- Investment in manufacturing infrastructure took INR400-500 crores over past decades, with ongoing optimization and utilization as a key asset.
2 more points from Fredun Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
PlannedSee what Fredun Pharmaceuticals Ltd said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
Rising- Fredun Pharmaceuticals maintains a steady orderbook with 6 to 7 months of orders always in hand.
- Currently, the company has confirmed orders upwards of INR 320 crores to INR 330 crores in hand.
- This robust order pipeline allows the company to give orders ahead to its suppliers, ensuring supply chain stability amid geopolitical changes.
2 more points from Fredun Pharmaceuticals Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Fredun Pharmaceuticals Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFredun Pharmaceuticals Ltd announcements
All announcements →- Acquisition / mergerNotableFredun Pharmaceuticals Ltd. acquires pet-wellness brand Furlicks from USV & Wellbeing Nutrition
Financials of Fredun Pharmaceuticals Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Fredun Pharmaceuticals Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 80 | 62 | 82 | 87 | 118 | 79 | 107 | 103 | 167 | 120 | 145 | 161 | 213 |
| Expenses + | 68 | 54 | 72 | 76 | 107 | 68 | 93 | 89 | 150 | 103 | 123 | 135 | 184 |
| Operating Profit | 12 | 8 | 10 | 11 | 11 | 10 | 14 | 13 | 17 | 17 | 22 | 26 | 29 |
| OPM % | 15% | 12% | 12% | 12% | 9% | 13% | 13% | 13% | 10% | 14% | 15% | 16% | 14% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 8 | 7 | 8 | 11 | 14 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 |
| Profit before tax | 8 | 4 | 6 | 6 | 6 | 6 | 8 | 7 | 8 | 9 | 13 | 14 | 12 |
| Tax % | 51% | 41% | 32% | 27% | 13% | 25% | 44% | 25% | 12% | 25% | 25% | 25% | 4% |
| Net Profit + | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 5 | 7 | 7 | 10 | 10 | 11 |
| EPS in Rs | 8.58 | 5.24 | 8.41 | 8.98 | 10.76 | 8.75 | 9.04 | 11.29 | 14.97 | 14.34 | 20.61 | 19.53 | 20.23 |
Financials of Fredun Pharmaceuticals Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 25 | 42 | 57 | 60 | 97 | 113 | 134 | 222 | 275 | 348 | 454 | 639 |
| Expenses + | 24 | 38 | 53 | 54 | 87 | 104 | 126 | 208 | 247 | 310 | 401 | 544 |
| Operating Profit | 2 | 4 | 3 | 6 | 10 | 8 | 8 | 14 | 28 | 38 | 53 | 95 |
| OPM % | 7% | 9% | 6% | 10% | 11% | 7% | 6% | 6% | 10% | 11% | 12% | 15% |
| Other Income + | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 2 | 0 |
| Interest | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 5 | 9 | 14 | 22 | 39 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 8 |
| Profit before tax | 1 | 2 | 2 | 3 | 6 | 2 | 3 | 9 | 18 | 21 | 28 | 48 |
| Tax % | 52% | 42% | 36% | 34% | 28% | 24% | 37% | 26% | 38% | 27% | 26% | 30% |
| Net Profit + | 0 | 1 | 1 | 2 | 4 | 2 | 2 | 6 | 11 | 16 | 21 | 33 |
| EPS in Rs | 1.11 | 4.55 | 6.08 | 5.11 | 11.18 | 4.76 | 5.04 | 14.30 | 23.85 | 33.22 | 44.07 | 60.68 |
| Dividend Payout % | 0% | 13% | 10% | 12% | 6% | 14% | 14% | 5% | 3% | 2% | 2% | 0% |
Financials of Fredun Pharmaceuticals Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 |
| Reserves | 0 | 1 | 2 | 19 | 35 | 37 | 39 | 64 | 92 | 117 | 137 | 273 |
| Borrowings + | 9 | 16 | 21 | 10 | 19 | 35 | 40 | 53 | 87 | 106 | 166 | 222 |
| Other Liabilities + | 11 | 24 | 30 | 47 | 47 | 65 | 79 | 66 | 74 | 81 | 179 | 141 |
| Total Liabilities | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 | 642 |
| Fixed Assets + | 8 | 15 | 16 | 16 | 31 | 31 | 30 | 32 | 39 | 47 | 53 | 118 |
| CWIP | 1 | 0 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Other Assets + | 14 | 29 | 36 | 52 | 74 | 110 | 131 | 155 | 218 | 260 | 433 | 522 |
| Total Assets | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 | 642 |
Financials of Fredun Pharmaceuticals Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 2 | 3 | 4 | 17 | 1 | -11 | 0 | -2 | -14 | -0 | -29 | 120 |
| Cash from Investing Activity + | -3 | -6 | -7 | -8 | -5 | -1 | -1 | -4 | -9 | -8 | -6 | -74 |
| Cash from Financing Activity + | 1 | 3 | 3 | -8 | 4 | 14 | -1 | 7 | 25 | 6 | 38 | 18 |
| Net Cash Flow | 0 | 1 | -1 | 1 | 0 | 2 | -2 | 1 | 1 | -2 | 3 | 65 |
| Free Cash Flow | -1 | -3 | -3 | 9 | -4 | -12 | -1 | -7 | -24 | -8 | -35 | 46 |
| CFO/OP | 108% | 85% | 117% | 303% | 8% | -128% | 2% | -17% | -52% | -1% | -55% | 126% |
Financials of Fredun Pharmaceuticals Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 98 | 131 | 94 | 67 | 126 | 112 | 148 | 46 | 68 | 142 | 53 |
| Inventory Days | 102 | 140 | 68 | 170 | 249 | 227 | 242 | 96 | 264 | 246 | 267 | 217 |
| Days Payable | 167 | 221 | 224 | 360 | 205 | 208 | 215 | 101 | 104 | 88 | 161 | 70 |
| Cash Conversion Cycle | 11 | 17 | -24 | -96 | 110 | 145 | 139 | 144 | 205 | 225 | 248 | 199 |
| Working Capital Days | -54 | -44 | -39 | 42 | 66 | 65 | 116 | 126 | 97 | 92 | 76 | 78 |
| ROCE % | 14% | 25% | 18% | 16% | 21% | 10% | 10% | 13% | 18% | 17% | 19% | 21% |
Guidance history
How Fredun Pharmaceuticals Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY26 call → | 20–40% | Up 2%+ | Planned | Planned | Rising |
| Q3 FY26 call → | 20–40% | Up 2%+ | Planned | Planned | — |
| Q2 FY26 call → | 10–20% | Flat | Planned | Planned | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
98 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +195.4% | 98% |
| Last 6 months | +140.9% | 98% |
| Last 3 months | +54.6% | 98% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Fredun Pharmaceuticals Ltd: 0.4 × 98 + 0.4 × 98 + 0.2 × 98 = 98.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 16 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Fredun Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
- Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
- IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL